Rockville, MD Business and Corporate Attorney News Archive

Sarepta Therapeutics is under intense scrutiny following the unfortunate death of a second patient who received its Elevidys gene therapy for Duchenne muscular dystrophy (DMD). The FDA is actively monitoring the situation, responding to concerns regarding acute liver failure associated with the therapy, particularly for non-ambulatory patients.

In light of these developments, Louise Rodino-Klapac, Sarepta's Chief Scientific Officer, affirmed the company’s dedication to patient safety. She announced a halt on Elevidys shipments for non-ambulatory individuals while the company conducts a thorough investigation.

The situation has raised alarms among legal and corporate analysts, including Kostas Biliouris from BMO Capital Markets in Chicago. Analysts are wary of possible regulatory changes under new FDA leadership. Furthermore, the ongoing civil litigation concerning Elevidys highlights critical issues about the future of this contentious treatment and emphasizes calls for increased oversight in the realms of business, corporate governance, and IP and technology law.